DOUBLE‐BLIND, RANDOMIZED COMPARISON OF ITRACONAZOLE CAPSULES AND PLACEBO IN ONYCHOMYCOSIS OF TOENAIL

HENRY EARL Jones,N. Zaias
DOI: https://doi.org/10.1111/j.1365-4362.1996.tb03667.x
1996-08-01
International Journal of Dermatology
Abstract:Patients and Methods Seventy-three men and women between the ages of 18 and 70 years were entered into a double-blinded study. All had Trichophyton rufarum-positive onychomycosis of the great toenail. Thirty-six of the patients were randomized to receive itraconazole, 200 mg daily for 12 weeks; and 37 patients received placebo. Table 1 summarizes the demographics of the patients. No significant differences were observed between treatment groups. Patients were randomly assigned to treatment with two 100-mg capsules once daily of itraconazole or placebo to be taken with a meal at the same time each day for 12 weeks. They were then evaluated by the investigators at weeks 4, 8, and 12 for healthy nail growth, percent of nail area involved, signs of onychomycosis, the investigator's global evaluation, and mycologically. The length of the unaffected nail part was measured and the progression or regression of infection was monitored. Profiles of serum chemical tests, including liver function tests and urinalysis, were monitored at baseline, and at weeks 4, 8, and 12. Women of childbearing potential also had a urinary pregnancy test at the start of therapy and at weeks 4, 8, and 12. Any unexplained or abnormal laboratory test value was repeated until the values returned to normal. Adverse events were also recorded.
What problem does this paper attempt to address?